You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
NAD 299 hydrochloride
Selective, high affinity 5-HT1A receptor antagonist (Ki = 0.6 nM in vitro). Enhances the action of selective 5-HT reuptake inhibitors and reverses citalopram-induced (Cat. No. 1427) inhibition of serotonergic cell firing.
Sold for research purposes under agreement from AstraZeneca
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 354.85. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.82 mL||14.09 mL||28.18 mL|
|5 mM||0.56 mL||2.82 mL||5.64 mL|
|10 mM||0.28 mL||1.41 mL||2.82 mL|
|50 mM||0.06 mL||0.28 mL||0.56 mL|
References are publications that support the biological activity of the product.
Larsson et al (1998) Differential regional antagonism of 8-OH-DPAT-induced decrease in serotonin synthesis by two 5-HT1A receptor antagonists. Eur.J.Pharmacol. 346 209 PMID: 9652362
Arborelius et al (1999) The 5-HT1A receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing. Eur.J.Pharmacol. 382 133 PMID: 10528148
Johansson et al (1997) The pharmacological characterization of a novel selective 5-hydroxytryptamine-1A receptor antagonist, NAD-299. J.Pharamacol.Exp.Ther. 283 216
If you know of a relevant reference for NAD 299 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: NAD 299 hydrochloride, NAD 299 hydrochloride supplier, AstraZeneca, 5-HT1A, serotonin, 5-HT, receptor, antagonists, NAD299, Receptors, 3282, Tocris Bioscience
1 Citation for NAD 299 hydrochloride
Citations are publications that use Tocris products. Selected citations for NAD 299 hydrochloride include:
Afshar et al (2019) Protective effects of 5-HT1A receptor antagonist and 5-HT2A receptor agonist on the biochemical and histological features in a rat model of Alzheimer's disease. J.Chem.Neuroanat. 96 140
Do you know of a great paper that uses NAD 299 hydrochloride from Tocris? Please let us know.
Reviews for NAD 299 hydrochloride
There are currently no reviews for this product. Be the first to review NAD 299 hydrochloride and earn rewards!
Have you used NAD 299 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.